SCYX plans Phase II trial of SCY-770 for ADPKD by year-end
SCYX said phase II trials for SCY-770 in ADPKD are set to begin by year-end, as part of its rare-disease pipeline following the acquisition of SCY-770.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.